sever
acut
respiratori
syndrom
sar
recent
emerg
diseas
associ
pneumonia
infect
patient
diseas
unusu
sever
patient
suffer
diseas
respond
empir
antimicrobi
treatment
acut
communityacquir
typic
atyp
pneumonia
end
march
cumul
total
case
death
report
countri
diseas
highli
infecti
attach
rate
report
healthcar
worker
care
sar
patient
recent
identifi
novel
viru
famili
coronavirida
sar
patient
patient
pair
acut
convalesc
sera
avail
seroconvert
greater
fourfold
increas
antibodi
titer
novel
viru
suggest
play
import
role
etiolog
sar
thu
establish
rapid
noninvas
test
viru
high
prioriti
monitor
control
diseas
report
realtim
quantit
pcr
assay
detect
viru
clinic
specimen
patient
clinic
diagnosi
sar
admit
two
hospit
hong
kong
februari
march
consid
studi
inclus
criteria
fever
higher
cough
short
breath
new
pulmonari
infiltr
chest
radiograph
either
histori
exposur
patient
sar
absenc
respons
empir
antimicrobi
coverag
typic
atyp
pneumonia
sampl
collect
inform
consent
total
sar
patient
pair
sera
nasopharyng
aspir
npa
sampl
avail
studi
diagnosi
sar
confirm
patient
presenc
antibodi
novel
coronaviru
serum
age
patient
rang
year
mean
sd
year
maletofemal
ratio
time
submit
manuscript
one
patient
die
npa
sampl
collect
suction
dispos
aspir
trap
contain
ml
viral
transport
medium
contain
per
liter
g
sodium
bicarbon
g
bovin
serum
albumin
vancomycin
amikacin
u
nystatin
earl
balanc
salt
solut
total
rna
npa
sampl
extract
use
qiaamp
viru
rna
mini
kit
qiagen
instruct
manufactur
elut
buffer
isol
rna
stool
specimen
viral
transport
medium
contain
suspend
stool
subject
rna
extract
method
describ
ten
microlit
elut
rna
reversetranscrib
use
u
superscript
ii
revers
transcriptas
invitrogen
reaction
contain
random
hexam
mm
dithiothreitol
mm
deoxynucleotid
triphosph
faststart
dna
master
sybr
green
fluoresc
reaction
roch
use
pcr
assay
briefli
cdna
amplifi
contain
per
liter
mmol
forward
primer
revers
primer
reaction
perform
lightcycl
roch
follow
condit
min
follow
cycl
plasmid
contain
target
sequenc
use
posit
control
fluoresc
signal
reaction
captur
end
extens
step
cycl
determin
specif
assay
pcr
product
subject
melt
curv
analysi
end
assay
basi
identifi
sequenc
viru
pair
primer
expect
amplifi
region
within
rnadepend
rna
polymeraseencod
sequenc
viru
access
use
assay
ident
product
confirm
sequenc
determin
dynam
rang
realtim
quantit
pcr
serial
dilut
plasmid
dna
contain
target
sequenc
made
subject
realtim
quantit
pcr
assay
assay
abl
distinguish
differ
concentr
rang
signal
observ
water
control
fig
posit
signal
observ
serolog
confirm
sar
patient
posit
case
uniqu
pcr
product
tm
correspond
signal
posit
control
observ
fig
data
shown
result
indic
assay
highli
specif
target
copi
number
target
sequenc
reaction
high
thu
mani
copi
viral
sequenc
present
npa
sampl
transport
medium
among
posit
case
copi
number
less
ie
low
calibr
ident
posit
signal
six
case
confirm
melt
curv
analysi
confirm
gel
electrophoresi
three
case
five
posit
case
npa
sampl
collect
seroconvers
viral
rna
detect
three
sampl
indic
assay
detect
viru
even
earli
stage
infect
valid
specif
assay
npa
sampl
healthi
individu
n
patient
suffer
adenoviru
n
respiratori
syncyti
viru
n
human
metapneumoviru
n
influenza
viru
n
influenza
b
viru
n
infect
recruit
neg
control
one
sampl
neg
assay
falseposit
case
neg
subsequ
test
taken
togeth
includ
initi
falseposit
case
realtim
quantit
pcr
assay
posit
sar
case
neg
control
without
viral
infect
epidemiolog
data
suggest
droplet
transmiss
one
major
rout
transmiss
viru
detect
live
viru
detect
high
copi
number
viral
sequenc
npa
sampl
current
studi
clearli
support
concept
cough
sneez
droplet
sar
patient
major
rout
spread
infecti
agent
time
write
manuscript
dispos
surgic
mask
glove
gown
worn
healthcar
worker
care
sar
patient
interestingli
two
four
avail
stool
sampl
sar
patient
studi
posit
assay
data
shown
thu
relev
note
mani
anim
coronavirus
spread
via
fecalor
rout
studi
requir
test
whether
viru
fece
infecti
addit
novel
human
coronaviru
two
known
serogroup
human
coronavirus
primer
set
use
assay
sequenc
homolog
correspond
sequenc
avail
genbank
known
whether
primer
would
crossreact
strain
howev
sequenc
analys
avail
sequenc
region
polymeras
gene
indic
human
viru
associ
sar
genet
distinct
furthermor
primer
use
studi
homolog
sequenc
known
coronavirus
thu
unlik
primer
would
hybrid
sequenc
strain
condit
assay
addit
novel
coronaviru
metapneumoviru
report
sar
patient
rna
sampl
studi
subject
nest
revers
transcriptionpcr
evid
metapneumoviru
infect
detect
patient
studi
data
shown
suggest
novel
coronaviru
key
player
pathogenesi
sar
work
requir
howev
determin
whether
pathogen
contribut
progress
diseas
work
use
sybr
green
detect
allow
melt
curv
analysi
thu
recognit
sampl
sequenc
variat
mutat
viru
may
import
virus
low
fidel
rnadepend
rna
polymeras
produc
high
mutat
rate
rna
virus
pcr
product
posit
case
studi
melt
point
strongli
suggest
viral
sequenc
variat
target
region
sampl
collect
two
hong
kong
hospit
period
patient
accrual
manuscript
revis
quantit
taqmanformat
assay
sarsassoci
coronaviru
publish
shown
posit
two
confirm
case
sar
taqman
method
complementari
target
differ
region
viru
moreov
demonstr
neg
result
patient
varieti
respiratori
viru
infect
complement
neg
find
taqman
assay
stool
patient
gastrointestin
symptom
support
concept
coronaviru
specif
sar
assay
also
add
inform
sequenc
variat
viru
assess
taqman
assay
rang
viral
copi
number
seen
rel
larg
number
patient
conclus
describ
simpl
rapid
noninvas
diagnost
test
novel
coronaviru
associ
sar
assay
posit
earli
diseas
modest
number
specimen
procedur
eg
rna
extract
revers
transcript
realtim
pcr
complet
h
test
hundr
suspect
sar
case
need
day
outbreak
also
adapt
protocol
highthroughput
format
expect
current
rapid
method
prompt
identif
pathogen
allow
prompt
identif
viru
thu
facilit
control
diseas
provis
prompt
appropri
treatment
patient
